Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Change in Cash (2016 - 2025)

Historic Change in Cash for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to -$76.8 million.

  • ImmunityBio's Change in Cash fell 32344.8% to -$76.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$51.0 million, marking a year-over-year increase of 2277.98%. This contributed to the annual value of -$121.9 million for FY2024, which is 17578.25% down from last year.
  • ImmunityBio's Change in Cash amounted to -$76.8 million in Q3 2025, which was down 32344.8% from $77.0 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Change in Cash registered a high of $134.5 million during Q3 2023, and its lowest value of -$144.7 million during Q1 2022.
  • In the last 5 years, ImmunityBio's Change in Cash had a median value of $480000.0 in 2022 and averaged $1.4 million.
  • Its Change in Cash has fluctuated over the past 5 years, first plummeted by 158213.85% in 2022, then soared by 1812708.33% in 2023.
  • Quarter analysis of 5 years shows ImmunityBio's Change in Cash stood at $116.6 million in 2021, then crashed by 99.59% to $480000.0 in 2022, then skyrocketed by 18127.08% to $87.5 million in 2023, then tumbled by 63.87% to $31.6 million in 2024, then crashed by 342.96% to -$76.8 million in 2025.
  • Its last three reported values are -$76.8 million in Q3 2025, $77.0 million for Q2 2025, and -$82.8 million during Q1 2025.